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The Gag proteins of HIV-1, like those of other retroviruses, are necessary and sufficient for the assembly of virus-like
particles. The roles played by HIV-1 Gag proteins during the life cycle are numerous and complex, involving not only assembly
but also virion maturation after particle release and early postentry steps in virus replication. As the individual Gag domains
carry out their diverse functions, they must engage in interactions with themselves, other Gag proteins, other viral proteins,
lipid, nucleic acid (DNA and RNA), and host cell proteins. This review briefly summarizes our current understanding of how
HIV-1 Gag proteins function in the virus life cycle.
INTRODUCTION
The HIV-1 Gag proteins are initially synthesized as a
polyprotein precursor which is sufficient to produce non-
infectious, virus-like particles in the absence of other
viral proteins or packageable viral RNA (for reviews, see
Wills and Craven, 1991; Hunter, 1994; Swanstrom and
Wills, 1997; Vogt, 1997). In the case of HIV-1, this Gag
precursor has been named, based on its apparent mo-
lecular weight, Pr55Gag. During or shortly after virus bud-
ding from the host cell, the HIV-1 protease (PR) cleaves
Pr55Gag into the mature Gag proteins p17 matrix (MA),
p24 capsid (CA), p7 nucleocapsid (NC), and p6 (Fig. 1A).
The proteolytic processing of Gag induces a major trans-
formation in virion structure: MA remains associated with
the inner face of the viral membrane, whereas CA con-
denses to form a shell around the viral RNA/NC complex.
This rearrangement, known as maturation, produces a
morphological transition to a particle with a conical core
characteristic of an infectious virion (Fig. 1B). The gen-
eral organization of the major Gag proteins (MA, CA, and
NC) in the Gag precursor and within the virion is highly
conserved among retroviruses (Wills and Craven, 1991;
Hunter, 1994; Swanstrom and Wills, 1997; Vogt, 1997).
Cleavage of Pr55Gag also generates two small spacer
peptides, p1 and p2 (Fig. 1A). Although precise functions
for these domains have not been established, their pres-
ence in Pr55Gag appears to regulate rates of cleavage at
the individual PR recognition sites and thereby influ-
ences the ordering of processing and virion morphogen-
esis (Pettit et al., 1994; Krausslich et al., 1995; Wiegers et
al., 1998).
Retroviral Gag proteins face a major challenge in car-
rying out their functions. During virus assembly, the Gag
proteins must assemble into higher-order, multimeric
structures that are directed outward to the plasma mem-
brane; in contrast, following virus entry, the same pro-
teins must disassemble or be directed inward toward the
nucleus. To some extent, this problem has been solved
by a strategy in which the Gag precursor carries out
assembly and membrane targeting functions while the
mature proteins, produced after virion release from the
cell, perform opposing functions of uncoating and disas-
sembly. In theory, differing functions for Gag domains in
the precursor versus the mature Gag proteins could have
been achieved in several ways: (1) Gag domains could
undergo major conformational (and thus functional)
changes following PR processing of the Gag precursor,
(2) functional domains in Gag could span cleavage sites
such that they are altered by PR cleavage, (3) Gag pro-
teins could undergo posttranslational modifications
which alter their function following virion release from
the cell, or (4) Gag proteins could associate with host cell
factors during virus entry which direct the viral proteins
along pathways not followed during assembly.
The HIV-1 life cycle can be considered as a sequence of
steps, depicted schematically in Fig. 2, which are regulated
by both viral and cellular proteins. Although the precise
ordering of many of these steps has not been definitively
determined and multiple steps are likely to occur in a
concerted, simultaneous fashion, the life cycle can be di-
vided into the following series of events: (1) The infection
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process begins when the surface (SU) envelope (Env) gly-
coprotein gp120 binds CD4 and interacts with coreceptor.
(2) A membrane fusion reaction, induced by the transmem-
brane (TM) Env glycoprotein gp41, occurs between the lipid
bilayer of the virion and the host cell plasma membrane,
releasing the viral core into the cytoplasm. (3) A series of
FIG. 1. Schematic representation of the HIV-1 genome and virion organization. (A) The location of the HIV-1 open reading frames is indicated. The
RNA encapsidation signal, c, is shown near the 59 end of the genome. The gag open reading frame is enlarged. (B) The HIV-1 virion, indicating the
approximate location of Gag proteins, the Env glycoproteins, and the pol-encoded enzymes IN, RT, and PR. The location of p6Gag in the virions has
not been definitively determined. Colors in the virion correspond to the location of the proteins in the Gag precursor. Details are provided in the text.
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ill-defined steps, referred to collectively as uncoating, takes
place. During this process, CA is lost, while at least some
MA, as well as NC, the pol-encoded enzymes integrase (IN)
and reverse transcriptase (RT), and the viral protein R (Vpr)
are thought to be retained as part of a high-molecular-
weight complex. (4) During uncoating, reverse transcription
of the viral RNA to generate a double-stranded DNA copy is
largely completed. (5) The high-molecular-weight complex,
now referred to as the preintegration complex is trans-
ported across the nuclear membrane. (6) In the nucleus,
integration of the viral DNA into the host cell chromosome
is catalyzed by IN. (7) The integrated viral DNA, known as
the provirus, serves as the template for the synthesis of
viral RNAs, which are transported to the cytoplasm. (8) The
Env glycoproteins are synthesized in the ER and are trans-
ported to the plasma membrane via the secretory pathway.
(9) The Gag and Gag-pol polyprotein precursors are syn-
thesized and transported by an unknown mechanism to the
plasma membrane. During or after transport, the Gag pre-
cursor recruits two copies of the single-stranded viral RNA
genome, interacts with the Gag-pol precursor, and assem-
bles into structures visible by electron microscopy as
dense patches lining the inner face of the plasma mem-
brane. (10) The assembled Gag protein complex induces
membrane curvature, leading to the formation of a bud. (11)
During budding, the viral Env glycoproteins are incorpo-
rated into the nascent particles. (12) Budding is completed
as the particle pinches off from the plasma membrane. And
(13) during or immediately after budding, the viral PR
cleaves the Gag and Gag-pol polyprotein precursors to the
mature Gag and Pol proteins. PR cleavage leads to core
condensation and the generation of a mature, infectious
virion which is now capable of initiating a new round of
infection.
MATRIX (MA)
MA, which forms the N-terminal domain of the Pr55Gag
precursor, has been implicated in the targeting of Gag to
the plasma membrane, Env glycoprotein incorporation
FIG. 2. The HIV-1 life cycle. Major steps in virus replication are indicated in a highly schematic form. The life cycle is subdivided into two stages:
early and late. Details are provided in the text.
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into virions, and early postentry events. The structure of
the HIV-1 MA protein has been determined by both NMR
spectroscopy and X-ray crystallography (Massiah et al.,
1994; Hill et al., 1996; Conte and Matthews, 1998). The
protein folds into a compact core domain, consisting
largely of a-helices and a three-stranded b-sheet (Fig.
3A). The C-terminal ;30 residues of MA form an a-helix
which may serve to connect MA and CA domains in
Pr55Gag. In the crystal structure, both HIV-1 and SIV MA
are trimeric (Rao et al., 1995; Hill et al., 1996). The bio-
logical relevance of trimerization is currently unclear,
although the formation of higher-order MA structures
would have implications for virus assembly and Env
glycoprotein incorporation into virions.
Membrane binding and Gag targeting
It is clear that a major function of the HIV-1 MA protein
is to direct binding to, and assembly at, the plasma
membrane. It was initially reported that mutation of the
N-terminal Gly residue, which serves as the site of myr-
istic acid attachment, blocked virus assembly and im-
paired binding of Gag to membrane (Gheysen et al.,
1989; Gottlinger et al., 1989; Bryant and Ratner, 1990; Pal
et al., 1990; Freed et al., 1994). Subsequently, it was
observed that single amino acid changes near the N
terminus of MA and in the vicinity of residues 55 and 85
also caused virus assembly defects (Freed et al., 1994).
A highly basic domain between MA residues 17 and 31
FIG. 3. Linear representation of the HIV-1 Gag genes, with some major domains indicated. Amino acid positions are shown over each diagram.
(A) MA. Domains in which point mutations affect virus assembly, membrane binding, Gag targeting, postentry steps, and Env incorporation are shown.
The region of MA which forms the main globular domain is indicated; the C terminus of MA projects away from the plane of the membrane. The
position of the highly basic domain near the N terminus is shown. (B) CA. The two major domains visualized by structural analyses, the N-terminal
‘‘core’’ and C-terminal ‘‘dimerization’’ domains are indicated. The CypA binding loop and MHR are shown. (C) NC. The amino acid sequence is indicated
and the two zinc-finger domains are shown. (D) p6. The two major currently recognized functional domains are shown: the N-terminal region involved
in virus release and the C-terminal Vpr-interacting sequence. See text for additional details.
4 MINIREVIEW
has been implicated in membrane binding (Yuan et al.,
1993; Zhou et al., 1994); based on structural and muta-
tional analyses of HIV-1 MA, it was proposed that this
basic domain, in conjunction with other basic residues
throughout the protein, forms a positively charged patch
which promotes membrane binding by interacting with
acidic phospholipids on the inner face of the lipid bilayer
(Yuan et al., 1993; Massiah et al., 1994; Zhou et al., 1994;
Hill et al., 1996). Interestingly, the structures of other
retroviral MA proteins suggest that they too may interact
with membrane by exposing a cluster of basic residues
to the inner face of the lipid bilayer (Christensen et al.,
1996; Matthews et al., 1996; Conte et al., 1997; McDonnell
et al., 1998). The domains of retroviral MA proteins in-
volved in membrane binding have been referred to as
‘‘M’’ domains (Parent et al., 1995). Mutation of HIV-1 MA
residue 6 impaired virus assembly and Gag membrane
binding without affecting myristylation (Freed et al., 1994;
Ono et al., 1997; Ono and Freed, unpublished results);
analysis of a viral revertant of this mutant revealed that
substitutions in the middle of MA or near its C terminus
could reverse the virus assembly defect (Ono et al.,
1997). Thus it is apparent that binding of MA to mem-
brane involves, directly or indirectly, at least several
domains throughout the protein. The observation that
MA itself binds membrane less efficiently than Pr55Gag
(Zhou and Resh, 1996; Spearman et al., 1997), together
with the finding that deletions in the C terminus of MA
(Zhou and Resh, 1996) or throughout the protein (Spear-
man et al., 1997) enhance membrane binding, led to the
proposal that in the Gag precursor the myristate moiety
is highly exposed and thus free to interact with mem-
brane, whereas in the mature MA protein, the N terminus
is partially buried. This so-called ‘‘myristyl switch’’ model
of membrane binding, which has been proposed in other
systems (McLaughlin and Aderam, 1995), could help
explain how a subset of MA protein might dissociate
from the lipid bilayer and associate with the viral core
and/or preintegration complex in the early steps of the
virus life cycle (see below). It has been suggested that
MA binding to membrane might be modulated by phos-
phorylation (Gallay et al., 1995a,b; Bukrinskaya et al.,
1996). According to this model, cellular kinases, which
are specifically incorporated into virions, induce phos-
phorylation of MA, thereby conferring a negative charge
sufficient to induce release from the lipid bilayer. At this
time, a biological role for MA phosphorylation needs to
be assessed further, particularly in light of the observed
equivalent degree of phosphorylation of MA which is
bound or not bound to membrane (Spearman et al.,
1997).
Although progress has been made in delineating the
domains of MA which promote binding of Gag to mem-
brane, the mechanism by which the plasma membrane is
specifically targeted, in preference to intracellular mem-
branes, is unclear. Several lines of evidence suggest that
MA plays an important role in this process. Membrane
binding and virus assembly can still be achieved if sub-
stantial portions of MA are deleted; however, in many
cases the proper targeting of assembly is disrupted. For
example, deletion of a large region of MA retargeted
virus assembly to the ER (Facke et al., 1993; Gallina et al.,
1994) and replacement of the entire MA sequence with
a heterologous membrane binding domain resulted in
promiscuous assembly at both plasma and intracel-
lular membranes (Reil et al., 1998). Intriguingly, single
amino acid changes between MA residues 84 and 88
redirect virus assembly to an intracellular compart-
ment, apparently the Golgi apparatus or Golgi-derived
vesicles (Freed et al., 1994; Ono and Freed, unpub-
lished). These point mutations may act by specifically
disrupting a plasma-membrane targeting signal or by
creating a novel signal that causes Gag to be retargeted.
Studies conducted with the Mason–Pfizer monkey virus
(M-PMV) demonstrated that mutations in MA could
switch assembly from the type D (cytosolic) to a type C
(plasma membrane) assembly pathway (Rhee and
Hunter, 1990). Thus the targeting of virus assembly, as
well as membrane binding itself, may be a common
function of retroviral MA proteins.
Env glycoprotein incorporation
The Env glycoprotein complex, consisting of the sur-
face (SU) and transmembrane (TM) glycoprotein, is in-
corporated into virions during virus budding from the
plasma membrane (for review, see Freed and Martin,
1995a). The observation that HIV-1 virus particles which
lack PR incorporate Env glycoproteins (Huang et al.,
1995) indicates that Env incorporation is mediated by
Pr55Gag. The close proximity of MA to the lipid bilayer
has encouraged speculation that a direct interaction may
take place between the cytoplasmic tail of TM and the
MA domain of Gag. Support for an interaction between
HIV-1 MA and the TM glycoprotein gp41 derives from
studies demonstrating that deletions (Yu et al., 1992b),
multiple amino acid substitutions (Dorfman et al., 1994b),
and single residue mutations (Freed and Martin, 1995b,
1996; Ono et al., 1997) in HIV-1 MA can block Env incor-
poration into virions. Furthermore, in HIV-1-visna Gag
chimeras, the presence of the HIV-1 MA facilitated virion
incorporation of HIV-1 Env (Dorfman et al., 1994b). Finally,
Env expression in polarized epithelial cells directs Gag
release from the basolateral surface; this polarized bud-
ding is abrogated by mutations in MA and truncations in
the gp41 cytoplasmic tail (Lodge et al., 1994). In apparent
contradiction, truncation of the entire cytoplasmic do-
main of gp41 does not block Env incorporation, and
heterologous retroviral Env glycoproteins can be effi-
ciently incorporated into HIV-1 virions (for review, see
Freed and Martin, 1995a). This discrepancy is in part
resolved by the finding that whereas single and multiple
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amino acid substitution mutations in HIV-1 MA can block
the incorporation of full-length HIV-1 Env into virions,
these changes have no effect on the incorporation of
truncated HIV-1 Env glycoproteins (Freed and Martin,
1995b, 1996; Mammano et al., 1995). Thus it appears that
while the incorporation of Envs with short cytoplasmic
tails into HIV-1 virions is independent of MA, the incor-
poration of full-length Env requires a specific interaction
with, or at least accommodation by, MA. Although a
direct interaction between HIV-1 MA and gp41 has been
detected in vitro (Cosson, 1996), it has been difficult to
corroborate these findings in virus-expressing cells. One
potential explanation for this difficulty is that Env–MA
interactions in vivo may require that both proteins main-
tain their multimeric states in addition to their interac-
tions with membrane and perhaps with host factors.
An appealing model for Env incorporation invokes an
interaction between sequences within the long cytoplas-
mic tail of gp41 and holes present in the lattice-like MA
structure formed upon MA trimerization (Hill et al., 1996).
In fact, the location of point mutations within MA which
disrupt Env incorporation (Freed and Martin, 1995b,
1996) is consistent with this model. However, the biolog-
ical relevance of MA trimerization awaits further investi-
gation. It also remains to be determined when the puta-
tive Env–MA interaction takes place during virus assem-
bly and whether this interaction plays a role in early
events following membrane fusion.
Early postentry steps
In addition to the roles of the MA domain of Pr55Gag
late in the virus life cycle, evidence supports a function
for the mature MA protein in an early step postinfection.
It has been reported that HIV-2 MA is present at low
levels in the viral core (Gallay et al., 1995b), and several
laboratories have detected the presence of MA in the
viral preintegration complex, which functions to transport
the viral DNA into the nucleus (Bukrinsky et al., 1993b;
Gallay et al., 1995a,b; Miller et al., 1997). The association
of MA with core structures suggests a role for MA fol-
lowing membrane fusion. In fact, mutations which impair
virus replication without affecting assembly and release
or Env incorporation have been described. It was ob-
served that these mutations caused a defect in the
amount of viral DNA synthesized postinfection (Yu et al.,
1992a; Reicin et al., 1995, 1996; Casella et al., 1997),
suggesting a defect early in the life cycle. A recent study
observed that specific MA mutations reduced the stabil-
ity of viral DNA synthesized postinfection, implying an
effect on the integrity of the high-molecular-weight com-
plex in which reverse transcription takes place (Kiernan
et al., 1998). Consistent with an effect on core structure
or stability, these MA mutations also reduced the effi-
ciency of virion reverse transcription in ‘‘endogenous’’ RT
assays (Kiernan et al., 1998), which measure RT activity
in gently disrupted virions using the viral RNA genome as
a template. An additional phenotype of these mutants
was observed: an increase in the apparent binding of
Gag to membrane (Kiernan et al., 1998). The increased
membrane binding elicited by these mutations may
cause MA to be retained in the lipid bilayer following
membrane fusion, thereby ultimately leading to degrada-
tion of the reverse transcription complex. A role for MA
early in the virus life cycle must be rationalized with
results indicating that mutants lacking all or most of MA
were still infectious in the presence of Env glycoproteins
containing short tails (the MuLV Env, or truncated HIV-1
Env) (Wang et al., 1993; Reil et al., 1998). These results
can be accommodated with current models for MA func-
tion by considering that mutations that disrupt normal
roles for MA (for example, Gag membrane binding) may
exert a negative effect not observed in the absence of
MA. Furthermore, it must be emphasized that infectivity
of MA-deleted mutants is observed only under restricted
conditions: in the presence of a heterologous membrane
binding domain, in specific cell types, and in the absence
of the wild-type HIV-1 Env (Reil et al., 1998).
In contrast to oncoretroviruses, which require that the
host cell undergoes mitosis for a productive infection to
be established, lentiviruses efficiently infect nondividing
cells. This property has important biological conse-
quences in allowing HIV-1 to infect terminally differenti-
ated monocyte-derived macrophages, which constitute a
major target for virus infection in vivo (Gartner et al.,
1986; Koenig et al., 1986). These observations have led to
the assumption that HIV-1 must encode protein(s) con-
taining nuclear localization signals (NLSs), which serve
to transport the viral preintegration complex to, and
across, the nuclear membrane. Initially, it was postulated
that MA provided this function: mutations in the highly
basic domain of MA (discussed above in the context of
membrane binding) were reported to specifically block
infection of nondividing cells, and BSA conjugated with
peptides derived from the highly basic domain localized
to the nucleus (Bukrinsky et al., 1993a). However, it was
subsequently reported that defective infectivity was ob-
served only in the context of virus isolates lacking a
functional viral protein R (Vpr) gene (Heinzinger et al.,
1994; von Schwedler et al., 1994), and a number of other
studies demonstrated that basic domain mutations did
not specifically block infection of nondividing cells, in-
cluding primary macrophages (Freed and Martin, 1994;
Freed et al., 1995; Fouchier et al., 1997; Nie et al., 1998;
Reil et al., 1998). Furthermore, attempts to biochemically
demonstrate the presence of an NLS in MA were unsuc-
cessful (Fouchier et al., 1997). As an extension of the
model invoking MA as a major determinant of nuclear
transport, it was proposed that phosphorylation of a Tyr
residue located at the C terminus of MA induced the
protein to dissociate from the plasma membrane and
associate specifically with integrase. Mutation of this
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C-terminal Tyr was reported to block infection of primary
macrophages (Gallay et al., 1995a); however, this result
was not confirmed in other studies (Bukrinskaya et al.,
1996; Freed et al., 1997). It is currently unclear what role
MA plays in actively directing nuclear import of the viral
preintegration complex in nondividing cells. MA either
does not function in this regard or provides a weak
signal that acts in conjunction with other viral proteins.
Vpr (Heinzinger et al., 1994) and integrase (Gallay et al.,
1997) have been implicated in this process.
CAPSID (CA)
In the mature virion, CA forms a shell surrounding the
viral RNA genome and core-associated proteins. The CA
domain of Pr55Gag plays an important role in virus as-
sembly, and the mature CA protein functions in virion
maturation and also appears to be involved in early
postentry steps. The CA protein is composed of two
domains: an N-terminal region (the so-called ‘‘core’’ do-
main, composed of residues 1–145), which functions in
virion maturation and incorporation of the cellular protein
cyclophilin A (CypA), and a C-terminal ‘‘dimerization’’ do-
main (residues 151–231), which contributes to Gag–Gag
interactions (Fig. 3B). Structural data for HIV-1 CA have
been obtained by both NMR spectroscopy (Gitti et al.,
1996) and X-ray crystallography (Gamble et al., 1996;
Momany et al., 1996). At this time, the structure of the
entire CA has not been resolved; rather, information is
available separately for the two domains mentioned
above. The core domain is highly helical, being com-
posed of seven a-helices, two b-hairpins, and an ex-
posed loop. The exposed loop serves as the binding site
for CypA (Gamble et al., 1996). The C-terminal CA domain
is globular, also with a high helical content (Gamble et
al., 1997). This domain contains the only region of Gag
that displays significant homology among different gen-
era of retroviruses: the major homology region (MHR)
(Wills and Craven, 1991).
Virus assembly and CypA binding
Mutational analysis of the CA domain of HIV-1 Pr55Gag
has defined specific sequences that affect virus assem-
bly. Specifically, mutations in the C-terminal third of CA
have been reported by a number of groups to impair
virus production (Jowett et al., 1992; Hong and Boulanger,
1993; von Poblotzki et al., 1993; Chazal et al., 1994;
Dorfman et al., 1994a; Mammano et al., 1994; Reicin et
al., 1995; Zhang et al., 1996; Kattenbeck et al., 1997).
These results suggested that the C-terminal domain of
CA might be involved in Gag–Gag interactions, a conclu-
sion borne out by more recent structural analyses (Gam-
ble et al., 1997). Mutations in the HIV-1 MHR produce a
broad array of phenotypes, with defects reported in virus
assembly, maturation, and infectivity (Mammano et al.,
1994). Rather than being directly involved in forming the
dimer interface, the highly conserved MHR residues form
a network of hydrogen bonds in the crystal structure that
stabilize the conformation of the entire domain (Gamble
et al., 1997). The importance of MHR residues to the
overall structure of the C-terminal domain of CA helps
explain the severity and diversity of phenotypes ob-
served with MHR mutations, since these changes may
induce global malfolding. In vitro, the mature HIV-1 CA
protein forms large oligomers, consistent with its role in
assembly (Ehrlich et al., 1992, 1994; von Schwedler et al.,
1998).
CA has also been reported to be required for the
incorporation of the Gag–Pol precursor into virions
(Smith et al., 1993; Srinivasakumar et al., 1995; Huang
and Martin, 1997), an event which is essential for the
recruitment of RT, IN, and PR into particles. A specific
region of CA required for the interaction of Gag with
Gag–Pol has not been precisely mapped, perhaps be-
cause this interaction involves a series of noncontiguous
domains within CA.
In a yeast two-hybrid screen for host cell proteins
which interact with HIV-1 Gag, it was revealed that mem-
bers of the cyclophilin family of proteins, which function
in the cell as peptidyl-prolyl cis-trans isomerases, inter-
act with HIV-1 Gag (Luban et al., 1993). One of these
family members, CypA, was found to be specifically in-
corporated into HIV-1 virions (Franke et al., 1994b; Thali
et al., 1994). Mutational analysis indicated that the do-
main responsible for CypA incorporation resided in the
vicinity of Pro 90 (Franke et al., 1994b); this conclusion
was confirmed by the cocrystallization of CA with CypA
(Gamble et al., 1996). The incorporation of CypA into
HIV-1 virions can also be blocked by treatment of virus-
producing cells with cyclosporine A or its nonimmuno-
suppressive analogs. Unfortunately, from the perspective
of antiviral therapy, variants that are resistant to, or even
dependent upon, the presence of these drugs rapidly
emerge (Aberham et al., 1996; Braaten et al., 1996a).
Interestingly, these resistant variants, which acquire mu-
tations in CA in the vicinity of the CypA binding site, still
bind CypA in vitro. Furthermore, CypA incorporation into
drug-resistant virions is still disrupted by cyclosporine A
(Braaten et al., 1996a). Thus these mutants have not
altered their ability to interact with CypA; rather, they no
longer require this interaction for efficient infection. Al-
though it is not clear what role CypA incorporation plays
in the virus life cycle, CypA-deficient HIV-1 virions exhibit
defects early postinfection (Thali et al., 1994; Stein-
kasserer et al., 1995; Braaten et al., 1996b). In the virion,
CypA packs with CA at a Gag:CypA ratio of ;10:1. The
N-terminal CA domain forms continuous planar strips; it
has been suggested that the intercalation of CypA in
these strips might loosen CA–CA interactions, thereby
facilitating uncoating after virus entry (Gamble et al.,
1996). This interesting hypothesis awaits confirmation.
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Virion maturation and early postentry events
Unlike mutations in the C-terminal domain of CA which
impair virus assembly, mutations in the N-terminal half of
the protein generally do not affect the efficiency of par-
ticle production. However, virions with N-terminal CA
mutations often display marked infectivity defects and
aberrant core morphology by EM (Jowett et al., 1992; von
Poblotzki et al., 1993; Wang and Barklis, 1993; Dorfman et
al., 1994a; Reicin et al., 1995, 1996). After PR-mediated
cleavage at the MA–CA junction, the N terminus of CA
apparently undergoes a refolding to form a b-hairpin/
helix structure that is stabilized by a salt bridge between
Pro 1 of CA and an Asp residue at position 51 (von
Schwedler et al., 1998). This refolding creates a new
CA–CA interface and may play a central role in core
condensation (von Schwedler et al., 1998). Consistent
with this hypothesis, recombinant CA in vitro formed
cylinders, while addition of as few as four or five C-
terminal MA residues to the N terminus of CA resulted in
the formation of spherical particles (Gross et al., 1998;
von Schwedler et al., 1998). In addition, mutations which
were specifically designed to disrupt the N-terminal in-
terface markedly reduced virus infectivity and blocked
normal core condensation in mutant virions (von Schw-
edler et al., 1998). The correlation between infectivity
defects and aberrant core morphology highlights the
importance of proper core condensation in early events
in the virus life cycle.
NUCLEOCAPSID (NC)
A distinguishing feature of HIV-1 NC proteins, both
structurally and functionally, is the presence of two Cys-
X2-Cys-X4-His-X4-Cys (CCHC) domains reminiscent of
the so-called zinc-finger motifs found in many cellular
DNA binding proteins (Fig. 3C). Each of the two zinc
fingers of HIV-1 NC (like those of other retroviruses)
coordinates a zinc ion (Summers et al., 1990, 1992; South
et al., 1990; Bess et al., 1992; South and Summers, 1993).
The existence of zinc-finger motifs in Gag NC proteins is
highly conserved among retroviruses; one or two such
domains are found in all retroviruses except the spuma-
viruses (Maurer et al., 1988). In virions, NC is found in the
core tightly associated with the viral RNA (Meric et al.,
1984). NMR analysis of HIV-1 NC indicates that the zinc-
finger domains are located in a central globular domain,
while the N and C termini of the protein are relatively
disordered (Morellet et al., 1992; South and Summers,
1993). The first finger is flanked on either side by highly
basic sequences. The NC domains of retroviral Gag
proteins were recognized early on as playing a role in
RNA binding and encapsidation; however, like the other
Gag domains, a variety of additional aspects of the virus
life cycle are reportedly influenced by HIV-1 NC. These
include RNA dimerization, Gag–Gag interactions, mem-
brane binding, reverse transcription (tRNA incorporation
and annealing to the primer binding site and strand
transfer), and stability of the preintegration complex.
RNA encapsidation
During virus assembly, HIV-1 encapsidates two copies
of the viral RNA genome per virion. Since PR-defective
HIV-1 virions contain viral RNA (Fu et al., 1994), encap-
sidation evidently involves contacts between the Pr55Gag
precursor and viral RNA during assembly. The process of
encapsidation strongly favors viral RNA over cellular
RNA and full-length, unspliced viral RNA over spliced
viral RNA. Mutations in the highly conserved Cys and His
residues of the HIV-1 NC zinc-finger domains caused
major defects in the specific encapsidation of full-length
viral RNA and in vitro RNA binding activity (Aldovini and
Young, 1990; Gorelick et al., 1990; Dorfman et al., 1993;
Zhang and Barklis, 1995, 1997; Schwartz et al., 1997). In
some cases, these mutations reduced the specificity of
encapsidation, resulting in an increased ratio of spliced
to unspliced RNA in virus particles (Zhang and Barklis,
1995; Schwartz et al., 1997). Mutations in basic residues
flanking the zinc fingers also reduced RNA binding in
vitro (Schmalzbauer et al., 1996) and RNA encapsidation
into virions (Poon et al., 1996). Retroviral Gag proteins
exhibit an additional level of specificity in that they en-
capsidate their cognate RNA genome more efficiently
than the genomes of other retroviruses. This specificity,
at least in some instances, is conferred by NC (Dupraz
and Spahr, 1992; Berkowitz et al., 1995; Zhang and Bark-
lis, 1995).
The primary domain in the viral RNA that is responsi-
ble for specific RNA packaging, known as the c site, is
located between the 59 long terminal repeat and the
beginning of the gag open reading frame (Aldovini and
Young, 1990; Clever et al., 1995; McBride and Pangani-
ban, 1996; Fig. 1A). In HIV-1, this domain has been pre-
dicted to fold into four stem-loops (SL1–SL4) with SL3
being particularly well conserved among virus isolates
(Clever et al., 1995). Although NC binds single-stranded
RNA relatively nonspecifically, it displays a strong pref-
erence for RNAs containing the c site; biochemical anal-
yses using Gag proteins expressed in vitro confirmed the
importance and specificity of HIV-1 NC in Gag–RNA
interactions (Luban and Goff, 1991; Berkowitz et al., 1993;
Berkowitz and Goff, 1994; Dannull et al., 1994; Clever et
al., 1995; Geigenmuller and Linial, 1996). Recently, the
structure of HIV-1 NC in a complex with the SL3 region of
HIV-1 c has been determined by NMR methods (De Guzman
et al., 1998). This structure provides some insights into the
specificity of NC–RNA interactions: NC basic residues at
positions 3 and 10 interact with the RNA major groove,
while the zinc fingers hydrogen bond with exposed
guanosines on the SL3 loop. The high-affinity interaction
between NC and SL3 is apparently assisted by extensive
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intramolecular interactions between the NC zinc-finger
domains (De Guzman et al., 1998).
HIV-1 NC has been reported to facilitate viral RNA
dimerization (Darlix et al., 1990; De Rocquigny et al.,
1992; Sakaguchi et al., 1993) and to mediate the conver-
sion of the dimeric RNA genome to a more stable form,
a process known as ‘‘RNA maturation’’ (Feng et al., 1996).
This latter observation suggests that NC acts as an RNA
chaperone (Herschlag, 1995) in that it catalyzes the con-
version of RNA to a thermodynamically stable conforma-
tion.
Virus assembly
During the course of studies aimed at characterizing
the role of NC in Gag function, it was observed that many
HIV-1 NC mutations caused defects in virus release,
suggesting that this domain of Pr55Gag plays a role in
virus assembly (Dorfman et al., 1993; Hong and Bou-
langer, 1993). Studies which analyzed HIV-1 Gag mutants
containing C-terminal deletions indicated that those trun-
cations which removed NC sequences abrogated effi-
cient assembly and release. The N-terminal basic do-
main of NC, rather than the zinc fingers, appeared to be
particularly important in this regard (Gheysen et al., 1989;
Hoshikawa et al., 1991; Jowett et al., 1992). Furthermore,
NC appears to play a role in the tight packing of Gag in
virions; deletions in NC led to the production of virions
with a lighter-than-normal density (Bennett et al., 1993).
Interestingly, Rous sarcoma virus (RSV) mutants which
produced low-density particles could be rescued to pro-
duce high-density particles by fusing small portions of
NC from heterologous retroviruses, including HIV-1, to
the RSV Gag (Bennett et al., 1993). Again, the highly basic
sequences rather than the zinc fingers appeared to be
particularly important in the formation of high-density
particles (Bennett et al., 1993). Studies analyzing Gag–
Gag interactions using yeast two-hybrid analysis sup-
ported a role for NC in mediating Gag multimerization
(Franke et al., 1994a), and HIV-1 CA–NC fusion proteins
assembled into cylinders in vitro more efficiently than CA
alone (Campbell and Vogt, 1995). Finally, it was recently
demonstrated that a heterologous domain known to me-
diate protein–protein interactions could substitute for NC
in the assembly of virus particles (Zhang et al., 1998). The
role of regions within retroviral NC proteins in mediating
Gag contacts has led to their designation as interaction
or ‘‘I’’ domains (Parent et al., 1995). These results, to-
gether with the data discussed above implicating CA in
virus assembly and Gag multimerization, argue that as-
sembly of authentic HIV-1 particles involves cooperative
interactions between multiple domains within Pr55Gag.
It is currently not clear what role RNA plays in facili-
tating virus assembly. The importance of NC basic resi-
dues, which promote NC–RNA interactions (De Roc-
quigny et al., 1992), suggests that RNA may form a
scaffold along which Gag molecules align and pack. The
contribution of RNA to Gag multimerization is supported
by in vitro assembly studies in which treatment of puri-
fied CA–NC proteins with RNase abolished assembly
(Campbell and Vogt, 1995). Reduced RNA encapsidation
resulting from NC basic residue mutations correlated
with defective core maturation, suggesting that NC–RNA
interactions may also be required for proper core mor-
phogenesis following PR-mediated Gag cleavage (Poon
et al., 1996).
It has been suggested that NC sequences are impor-
tant for efficient binding of HIV-1 Gag to membrane and
for specific Gag targeting to the plasma membrane. In a
cell-free system, in vitro synthesized Pr55Gag bound
membrane efficiently, whereas C-terminally truncated
molecules lacking NC sequences were reduced in their
membrane-binding ability (Platt and Haffar, 1994). More
recently, Gag truncation mutations that removed a region
near the N terminus of NC were reported to reduce
plasma membrane targeting of Pr55Gag in a mammalian
cell expression system (Sandefur et al., 1998). Since the
domain responsible for this phenomenon is also re-
quired for the production of dense particles, the role of
NC in membrane binding may be indirect and result from
effects on Gag–Gag interactions. Gag multimerization
may optimize efficient membrane binding, a hypothesis
supported by the analysis of high-molecular-weight com-
plexes which form in the absence of efficient membrane
binding (Lee and Yu, 1998). Alternatively, sequences in
NC may influence the conformation of the N terminus of
Gag (i.e., MA), thereby enhancing membrane binding and
perhaps uncovering a plasma membrane targeting sig-
nal.
Early postentry steps and reverse transcription
It is well established that the NC domain of Pr55Gag
plays a role in RNA encapsidation and virus assembly.
However, NC mutations can block virus infectivity with-
out affecting particle assembly and release or the levels
of full-length genomic RNA in virions. Consistent with a
role for the mature NC protein early in the virus life cycle,
the nucleic acid annealing properties of NC assist in
several steps required for efficient reverse transcription.
The primer for HIV-1 reverse transcription is a tRNALys
(Jiang et al., 1993) that is specifically incorporated into
virions during assembly and binds to a sequence known
as the primer binding site (PBS) located near the N
terminus of the genome. NC stimulates the binding of
tRNALys to the PBS, specific initiation of reverse tran-
scription from the bound tRNALys, and efficient strand
transfer during reverse transcription (De Rocquigny et al.,
1992; Peliska et al., 1994; Tsuchihashi and Brown, 1994;
You and McHenry, 1994; Darlix et al., 1995; Rodriguez-
Rodriguez et al., 1995; Li et al., 1996; Guo et al., 1997). In
addition, the selective incorporation of tRNALys was re-
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portedly blocked by mutations in HIV-1 NC. Since
Pr160Gag-pol, rather than Pr55Gag, influences the specific-
ity of tRNA incorporation (Mak et al., 1994), it was pro-
posed that the mutations affected binding of tRNALys to a
Pr55Gag/Pr160Gag-pol complex (Huang et al., 1997). De-
tailed analyses of the basic residues in HIV-1 NC re-
vealed that some mutations reduced infectivity to a much
greater extent than RNA encapsidation (Ottmann et al.,
1995; Poon et al., 1996; Berthoux et al., 1997), and in
murine leukemia virus (MuLV), changing zinc-coordinat-
ing residues from Cys to His or His to Cys in the (single)
CCHC zinc finger led to the production of noninfectious
virions containing the full complement of viral RNA.
These virions were blocked at an early step in reverse
transcription (Gorelick et al., 1996). NC may also function
in stabilizing viral DNA early postsynthesis; HIV-1 NC can
protect viral DNA fragments from nuclease digestion in
vitro (Lapadat-Tapolsky et al., 1993), and NC mutations
were described that apparently caused degradation of
viral DNA synthesized postinfection (Berthoux et al.,
1997).
Antivirals
Several considerations have made NC an attractive
target for the design of anti-HIV compounds: (i) it func-
tions both early and late in the virus life cycle, (ii) it is
highly conserved among virus isolates (Myers et al.,
1993), and (iii) the CCHC type of zinc-finger motif that is
critical for retroviral NC function is relatively rare among
cellular proteins, which typically contain CCHH or CCCC
motifs (Berg and Shi, 1996). This latter observation raises
the possibility that compounds could be developed
which specifically target NC zinc fingers without blocking
the function of their cellular counterparts. A number of
compounds were shown to react with retroviral zinc
fingers, causing zinc to be ejected and NC function to be
destroyed (Rice et al., 1995; Tummino et al., 1996; Turpin
et al., 1996). This inactivation is irreversible due to the
formation of inter-and intramolecular disulfide crosslinks
between zinc-finger Cys residues following zinc ejection.
As a result, the ability of PR to process Pr55Gag is dis-
rupted (Turpin et al., 1996). The zinc-ejecting compounds
block zinc-dependent binding of HIV-1 NC to RNAs con-
taining the c site (Tummino et al., 1996) and inhibit HIV-1
infectivity in culture (Rice et al., 1993). A recent study
analyzing the effect of zinc-ejecting compounds on MuLV
replication and disease induction in mice demonstrated
that one compound, Aldrithiol-2, displayed antiviral ef-
fects in vivo (Ott et al., 1998).
p6
In addition to the MA, CA, and NC domains, whose
presence is highly conserved among retroviruses, the
gag genes of individual retrovirus genera often encode
additional open reading frames whose functions have
been less intensively investigated. In the case of HIV-1, a
small Pro-rich protein, p6, is located at the C terminus of
Gag (Fig. 1). An initial study demonstrated that truncation
of p6 caused severely impaired virus release; this defect
was characterized by an apparent accumulation of virus
particles at the plasma membrane (Gottlinger et al.,
1991). Many of these particles were tethered to the mem-
brane, suggesting a block at a very late step in budding.
Several subsequent studies, mostly using Gag-only ex-
pression systems, failed to observe a role for p6 in virus
release (Hoshikawa et al., 1991; Royer et al., 1991; Jowett
et al., 1992; Paxton et al., 1993). However, using a full-
length HIV-1 molecular clone, a requirement for p6 in
virus release was confirmed (Huang et al., 1995). By
evaluating a number of truncation and single amino acid
substitution mutants, the domain responsible for the
budding defect was mapped to a Pro-Thr-Ala-Pro-Pro
(PTAP) sequence near the N terminus of the protein;
sequences downstream in p6 were largely dispensable
for virus release (Gottlinger et al., 1991; Huang et al.,
1995; Fig. 3D). The result that inactivation of PR partially
suppressed the p6 virus release defect (Huang et al.,
1995) helped reconcile studies reporting a requirement
for p6 in virus release with those not seeing an effect of
p6 deletion, since most of the latter studies used sys-
tems in which only Gag was expressed. However, the
severity of the p6 virus release defect varies between
studies and appears to be at least partly dependent on
the cell type in which Gag is expressed (Yu et al., 1995;
Schwartz et al., 1996). It has also been reported that p6
mutations reduce the level of pol-derived proteins in
virions; again, this defect was partially suppressed by
inactivation of PR (Yu et al., 1998).
A similar late release function for Gag has been de-
scribed for other retroviruses, prompting these se-
quences to be collectively called ‘‘late’’ or ‘‘L’’ domains
(Parent et al., 1995). In RSV, this domain maps to a small
Pro-rich sequence, p2b, located between MA and Gag
p10 (Wills et al., 1994; Xiang et al., 1996). In the lentivirus
equine infectious anemia virus (EIAV), a protein known
as p9 serves this function (Puffer et al., 1997). Intriguingly,
HIV-1 p6 and EIAV p9 can replace the p2b function in
RSV, in a manner independent of the location of the late
domain in the Gag precursor (Parent et al., 1995). Al-
though it is currently not understood by what mechanism
retroviral late domains function, each of these proteins
contains a motif (PTAP for HIV-1 p6, PPPY for RSV p2b,
and YXXL for EIAV) known to mediate cellular protein–
protein interactions. It has been suggested that these
domains engage in interactions with host proteins at the
plasma membrane which facilitate the final step of virus
release (Garnier et al., 1996).
An additional role for HIV-1 p6 has been described.
Truncations in p6 result in the production of virus parti-
cles lacking the Vpr protein; this function maps to a
domain near the C terminus of p6 (Paxton et al., 1993; Lu
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et al., 1995; Kondo and Gottlinger, 1996). It is not clear
where in the virion p6 is localized or whether p6/Vpr
interactions persist following virus release.
CONCLUDING REMARKS
A large number of studies, many of which are dis-
cussed above, have contributed significantly to our
knowledge of how retroviral Gag proteins function in
virus replication. Despite this wealth of knowledge, many
questions remain unanswered. For example, during virus
assembly and release, it is not clear how HIV-1 Gag
specifically traffics to the plasma membrane, how and
where Gag multimerization is accomplished, how Gag
influences the recruitment of Env glycoproteins into viri-
ons, what drives the final steps in virus release, and what
rearrangements in protein conformation and interactions
take place during PR-mediated virion maturation. Even
more mysteries surround the early steps in the virus life
cycle. These events are particularly difficult to study
because of the high ratio of defective to infectious par-
ticles characteristic of retroviral preparations and the
large amount of viral protein uptake into target cells even
in the absence of a productive infection (Marechal et al.,
1998). Details of how uncoating and nuclear import take
place are particularly poorly understood. It must be as-
sumed that throughout the life cycle host cell proteins
actively participate in Gag function, yet little is known
about which cellular proteins are involved and what roles
they might play. The answers to these and related ques-
tions await further investigation.
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